Post by CareValidate

Interest in peptides grew an estimated 20x last year. The patient demand is real, and it's a different kind of patient than most telehealth operators are used to. Peptide patients tend to be high-LTV, recurring, and actively invested in their outcomes. They're not looking for a quick fix. They're looking for a program with clinical credibility, and back it up with a care pathway that supports them over time. That's a meaningful shift from the patient experience of GLP-1s. The results aren't as immediate and visible. The education curve is steeper. But the retention profile and the margin opportunity are both significant for operators who build this correctly. The consumer interest is here. The regulatory moment is arriving. The window to build a peptide offering the right way: with clinical depth, not just speed to market, is now. We put together a full playbook on the current landscape of peptides across consumer interest, clinical pathways, and business approach. Link in the comments.